菊明降压丸联合替米沙坦治疗原发性高血压的临床研究  

Clinical study on Juming Jiangya Pills combined with telmisartan in treatment of essential hypertension

作　　者：贾魁[1] 李志娟[1] 邢适颖[1] JIA Kui;LI Zhi-juan;XING Shi-ying(Department of Cardiology,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,China)

机构地区：[1]河南科技大学第一附属医院心血管内科,河南洛阳471000

出　　处：《现代药物与临床》2021年第2期335-339,共5页Drugs & Clinic

摘　　要：目的探讨菊明降压丸联合替米沙坦片治疗原发性高血压的临床疗效。方法选择2020年2月—2020年7月在河南科技大学第一附属医院治疗的96例原发性高血压患者,根据入院顺序分为对照组(48例)和治疗组(48例)。对照组口服替米沙坦片,40 mg/次,血压控制不理想可增至80 mg/次,1次/d;治疗组在对照组的基础上口服菊明降压丸,6 g/次,3次/d。两组患者治疗4周。观察两组患者临床疗效,同时比较治疗前后两组患者血压水平、临床症状消失时间,血清同型半胱氨酸(Hcy)、血管紧张素Ⅱ(AngⅡ)、胰岛素样生长因子-1(IGF-1)、可溶性凝集素样氧化低密度脂蛋白受体1(s LOX-1)、单核细胞趋化蛋白-1(MCP-1)和血管紧张素转化酶(ACE)水平及血管内皮功能。结果治疗后,对照组临床有效率为81.25%,显著低于治疗组的97.92%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者收缩压(SBP)、舒张压(DBP)均下降(P<0.05),并且治疗组血压水平明显好于对照组(P<0.05)。治疗后,治疗组症状消失时间明显早于对照组(P<0.05)。治疗后,两组患者血清Hcy、AngⅡ、IGF-1、sLOX-1、MCP-1、ACE水平均下降(P<0.05),且治疗组患者降低更显著(P<0.05)。治疗后,两组患者肱动脉内皮依赖性舒张功能(EDD)、肱动脉非内皮依赖的舒张功能(NMD)均显著升高(P<0.05),且治疗组患者升高更明显(P<0.05)。结论菊明降压丸联合替米沙坦片治疗原发性高血压患者可有效改善患者临床症状,降低机体细胞因子水平,具有一定的临床推广应用价值。Objective To investigate the clinical efficacy of Juming Jiangya Pills combined with telmisartan in treatment of essential hypertension. Methods Patients(96 cases) with essential hypertension in the First Affiliated Hospital of Henan University of Science and Technology from February 2020 to July 2020 were divided into control(48 cases) and treatment(48 cases) groups based on visiting sequence. Patients in the control group were po administered with Telmisartan Tablets, 40 mg/time, and increased to 80 mg/time under unsatisfactory control of blood pressure, once daily. Patients in the treatment group were po administered with Juming Jiangya Pills on the basis of the control group, 6 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the blood pressure, the disappearance time of clinical symptoms, and the serum levels of Hcy, AngⅡ, IGF-1, sLOX-1, MCP-1 and ACE, and the vascular endothelial function in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.25%, which was significantly lower than 97.92% in the treatment group, and there were differences between two groups(P < 0.05). After treatment, the SBP and DBP in two groups were significantly decreased(P < 0.05), and the blood pressure in the treatment group was significantly better than that in the control group(P < 0.05). After treatment, the disappearance time of clinical symptoms in the treatment group was significantly earlier than that in the control group(P < 0.05). After treatment, the serum levels of Hcy, AngⅡ, IGF-1, sLOX-1, MCP-1, and ACE in two groups were significantly decreased(P < 0.05), and which in the treatment group were significantly lower than those in the control group(P < 0.05). After treatment, the EDD and NMD levels in two groups were significantly increased(P < 0.05), and which in the treatment group were significantly higher than those in the control group(P < 0.05). Conclusion

关 键 词：菊明降压丸 替米沙坦片 原发性高血压 同型半胱氨酸 胰岛素样生长因子-1 血管紧张素转化酶 血管内皮 

分 类 号：R972[医药卫生—药品]